Recruiting

Genomic Screening

Sponsor:

Columbia University

Code:

NCT05990179

Conditions

Early Onset Genetic Conditions With Near Complete Penetrance

Eligibility Criteria

Sex: All

Age: 0

Healthy Volunteers: Accepted

Interventions

Genome sequencing-based newborn screening

Study Details

Brief summary:

The goal of this study is to learn how genomic sequencing technology can be used to effectively expand the conditions screened on newborn screening. Newborn screening ensures equity and allows all babies to have the same chance at the healthiest life. Families will be invited to have their newborn baby screened for additional conditions beyond what all babies are screened for as part of the newborn screening public health program. Families can choose to be part of the study or choose not to be part of the study and just have the routine newborn screening test. Families will also be able to choose to learn about their baby's risk for conditions that have effective treatments available but are not on the routine newborn screening panel or also learn about conditions for which there is not currently FDA approved medications but for which medications are under development or for which early intervention services or treatment of seizures may improve the child's outcome. Families will be invited to the study shortly after the baby is born and will learn the decision not to participate, and we will interview a subset of parents who agree to be interviewed. Newborns who screen positive will be referred to appropriate providers for care and will be followed through review of electronic medical records and parental follow up via phone, text, postal mail or email.

Conditions

Early Onset Genetic Conditions With Near Complete Penetrance

Study ID

NCT05990179

Start date

Sep 6, 2022

Status verified date

Sep, 2025

Completion date

Sep, 2029

Anticipated

Primary completion date

Sep, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Newborns admitted to the well-baby nurseries from the recruiting hospitals
  • Newborns born after 33 weeks of gestation
  • Newborns whose parents are English, Mandarin, or Spanish speaking

Study Design

Enrollment

100000 participants

Anticipated

Intervention Model

Single group

Primary purpose

Screening

Interventions and Outcome Measures

Arms

experimental: Enrolled in the study

All newborns enrolled in the study will be evaluated.

Interventions

Genome sequencing-based newborn screening

Dried blood spots collected at birth for routine newborn screening will be used for genome sequencing based screening of a defined set of conditions.

Primary outcome measure

  • Enrollment Rate (percentage) [ Time Frame: From study launch to end of enrollment (up to 5 years) ]
  • Successful Sequencing Rate (percentage) [ Time Frame: Up to 6 months after the end of enrollment ]
  • Screen Positive Rate (percentage) [ Time Frame: Up to 6 months after the end of enrollment ]
  • True Positive Rate (percentage) [ Time Frame: Up to 6 months after the end of enrollment ]

Central Contacts and Locations

Central contacts

Locations

Columbia University Irving Medical Center/NYP

Recruiting

New York, New York, United States, 10032

Contacts

Principal Investigator:

Rudolph Leibel, MD

More Information

Sponsor

Columbia University

Last update posted

Sep 19, 2025

Last verified

Sep, 2025

Keywords

  • Newborn screening
  • Genome sequencing

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Columbia University on 2025-09-19.